SOUTH AFRICA – AstraZeneca has announced that it will be providing sponsorship to BrandMed towards the establishment of fifteen BrandMed Syntro-P Health Centers of Excellence as part of its commitment to work towards a future where all patients have access to sustainable, holistic health experiences and access to life-changing treatment and prevention.
Through the partnership with BrandMed, a leading South African connected healthcare company that integrates medical and lifestyle expertise and science with ground-breaking technologies, patients will soon have access to the additional BrandMed Syntro P Health Centers of Excellence that shift the focus from a fragmented silo approach to managing the world’s leading causes of morbidity and mortality, to a proactive, patient-centric, integrated risk-reduction and treatment approach.
The COVID-19 pandemic and the growing burden of non-communicable diseases (NCDs) have compelled healthcare stakeholders to explore new ways of improving health systems, stimulating the advancement of healthcare ecosystems that focus on enhancing the patient experience, improving treatment outcomes, while at the same time reducing expenses and treatment timelines.
This initiative with AstraZeneca is a further commitment to make life a little easier for those managing chronic conditions.
“Challenging times require a fresh innovative and integrated approach to healthcare. At BrandMed we are continuously reimagining health, using technology that empowers a better quality of life, not only for patients but for our healthcare practitioners too. This initiative with AstraZeneca is a further commitment to make life a little easier for those managing chronic conditions,” Dr Riaz Motara, Physician, Cardiologist and CEO of BrandMed said.
AstraZeneca has exemplified massive success in its investment in Africa’s NCDs healthcare through its Healthy Heart Africa (HHA) innovative program, committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) across Africa.
Since launching in Kenya in 2014, Ethiopia in 2016, Tanzania in 2018, Ghana in 2019, Uganda in 2020 and Côte d’Ivoire in 2021, HHA has been able to achieve impeccable milestones.
The program has conducted over 18.3 million blood pressure screenings in the community and in healthcare facilities, trained over 7,600 healthcare workers, including doctors, nurses, community health volunteers and pharmacists to provide education and awareness, screening and treatment services for hypertension.
Additionally, HHA activated over 900 healthcare facilities in Africa to provide hypertension services, including the establishment of secure supply chains for low cost, high-quality branded antihypertensive medicines, where applicable.
HHA aspires to reach 10 million people with elevated blood pressure across Africa by 2025, by increasing awareness and educating around lifestyle choice and CVD risk factors, training providers and driving care to lower levels of the healthcare system and facilitating access to low cost, high quality branded anti-hypertensives, where applicable.